Posted in | News | Nanobusiness

Owlstone Receives Cambridge Phenomenon Award 2010

Advance Nanotech, Inc. (OTCBB: AVNA) is pleased to report that Owlstone, Inc. ("Owlstone") has won the coveted and prestigious Cambridge Phenomenon Award 2010 at the 50th Anniversary of The Cambridge Phenomenon Conference "Future Starts Here". Owlstone was voted Cambridge's most exciting company for the future in its field by delegates of the conference.

In celebration of the 50th Anniversary of The Cambridge Phenomenon and hosted in partnership with Microsoft Research, ARM and Price Bailey, the conference drew on the opinions of some 300 high profile business and technology participants to identify winners from a shortlist of companies preselected by a panel of expert judges with backgrounds in investment, multinational corporations and government. In its 50 year history, Cambridge Phenomenon has been the catalyst for huge growth in more than 1,400 companies, including billion dollar successes such as ARM, Autonomy, Aveva, Cambridge Antibody Technologies, Cambridge Silicon Radio, Solexa and Virata.

In a letter to Owlstone shareholders, Bret Bader, CEO of Owlstone, commented, "We are delighted to win this significant award, not least because the judging panel was made up of such a large number of influential and experienced people from a variety of backgrounds. Although right now we are heavily involved in product development within the military, security and food industries, we consider this external validation of our future potential to be highly encouraging."

Source: http://www.advancenanotech.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.